(redirected from Cyclin-dependent kinase)
Also found in: Dictionary, Thesaurus, Medical, Encyclopedia, Wikipedia.
Category filter:
CDKCyclin-Dependent Kinase
CDKCore Design Kit
CDKConnector Development Kit
CDKComponent Development Kit
CDKCluster Development Kit
CDKCrypto Development Kit
CDKCyberspace Developer Kit
CDKControl Development Kit
CDKC Decay (physics)
CDKComité Départemental de Karaté (French: Departmental Committee of Karate)
CDKCompagnie du Komo (French; African holding company; Libreville, Gabon)
CDKCermin Dunia Kedokteran (Indonesian: Mirror World Medical; journal)
CDKCri du Kangourou (French skate shop)
CDKCountry Dancing in Kalamazoo (Kalamazoo, MI)
CDKCercle Damien Kandolo (French; African Masonic group)
CDKContainerized Deployment Kitchen
CDKCasein-Dependant Kinase
CDKCyclin Dependent Kinase Holoenzyme
CDKChannel Data Check
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
Lin et al., "Cyclin-dependent kinase 5 modulates STAT3 and androgen receptor activation through phosphorylation of ser727 on STAT3 in prostate cancer cells," The American Journal of Physiology-Endocrinology and Metabolism, vol.
Leitch et al., "Induction of eosinophil apoptosis by the cyclin-dependent kinase inhibitor AT7519 promotes the resolution of eosinophil-dominant allergic inflammation," PLoS ONE, vol.
Curto et al., "Potentiation of paclitaxel-induced apoptosis by the novel cyclin-dependent kinase inhibitor NU6140: a possible role for survivin downregulation," Molecular Cancer Therapeutics, vol.
p27 is a cyclin-dependent kinase (CDK) inhibitor whose specific late G1 destruction allows progression of the cell across the G1/S boundary.
The production of p2l (WAF1) is an essential component of this process due to its role as a cyclin-dependent kinase inhibitor.
EMPOWER (Utilisation and outcomes of Eribulin Mesylate POst a cyclin-dependent kinase 4/6 inhibitor: An observational real-World study in UnitEd States community oncology pRactices) was a retrospective, observational cohort study evaluating the use of eribulin in female patients with HR-positive HER2-negative metastatic breast cancer who received CDK 4/6 inhibitor therapy between February 2015 and December 2017.
The company added TP-1287 is an investigational oral cyclin-dependent kinase 9 (CDK9) inhibitor entering into a Phase 1 study in patients with advanced solid tumours (NCT03604783).
It has an essential role in differentiation of neural stems cells and neural progenitor cells (34), and its downregulation promotes growth, invasiveness, and metastasis (35) by targeting laminin, gamma 1 (LAMC1), integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12) (ITGB1), cyclin-dependent kinase 6 (CDK6), and SRY (sex determining region Y)-box9 (SOX9) (36).
It is well documented that cell cycle is controlled by the sequential formation, activation, and inactivation of a series of cell cycle regulators, that is, cyclins, cyclin-dependent kinases (CDK), and cyclin-dependent kinase inhibitors (CKIs).
Membranes were blocked with 5% nonfat milk in TBS (10 mM Tris and 100 mM NaCl) for 1h and probed with the primary antibodies (Santa Cruz, USA) against cyclin-dependent kinase (CDK)-4, CDK6, cyclin D, and [beta]-actin, respectively, followed by horseradish peroxidase-conjugated secondary antibody (Zhongshan, China) and ECL detection.
p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest.
EXPERIMENTAL DESIGN: HCC cells were treated with vitamin K2 and the expression of several growth-related genes including cyclin-dependent kinase inhibitors and cyclin D1 was examined at the mRNA and protein levels.